To verify the effects of nilotinib on DDR1 activity, we show that the level of CSF pDDR1 in placebo-treated AD patients (Fig. 2A) was significantly increased between baseline and end of treatment (slope = 1.003, p = 0.04). Here, DDR1 is linked to Alzheimer disease.